abstract |
Biomarkers, methods, devices, reagents, systems, and kits used to assess an individual having heart failure with preserved ejection fraction (HFpEF) or having heart failure with reduced ejection fraction (HFrEF) for the prediction of risk of developing a Cardiovascular (CV) Event over a 90 day, 180 day, or 1 year period are provided. |